Long overall survival after dendritic cell vaccination in metastatic uveal Melanoma Patients

American Journal of Ophthalmology

Volumn 158, Issue 5, 2014, Pages 939-947.e5

  Bol, Kalijn F ^a,b   Mensink, Hanneke W ^c,d   Aarntzen, Erik H J G ^a,b   Schreibelt, Gerty ^a   Keunen, Jan E E ^b   Coulie, Pierre G ^e   De Klein, Annelies ^d   Punt, Cornelis J A ^f   Paridaens, Dion ^c   Figdor, Carl G ^a   De Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROTTERDAM EYE HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DE DUVE INSTITUTE   (Belgium)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; CANCER VACCINE; MELANOCYTE PROTEIN PMEL 17;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DENDRITIC CELL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE ERYTHEMA; MALE; METASTATIC UVEAL MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR IMMUNITY; UVEA MELANOMA; CONTROLLED STUDY; EPIDEMIOLOGY; FOLLOW UP; IMMUNOLOGY; MELANOMA; METASTASIS; MORTALITY; NETHERLANDS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TIME; TRENDS; UVEAL NEOPLASMS; VACCINATION;

CANCER VACCINES; DENDRITIC CELLS; FOLLOW-UP STUDIES; GP100 MELANOMA ANTIGEN; HUMANS; MELANOMA; NEOPLASM METASTASIS; NETHERLANDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UVEAL NEOPLASMS; VACCINATION;

EID: 84908667491     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.07.014     Document Type: Article

References (63)

1. G. Virgili, G. Gatta, and L. Ciccolallo Incidence of uveal melanoma in Europe Ophthalmology 114 12 2007 2309 2315
2. A.D. Singh, M.E. Turell, and A.K. Topham Uveal melanoma: trends in incidence, treatment, and survival Ophthalmology 118 9 2011 1881 1885
3. C.L. Shields, S. Kaliki, M. Furuta, A. Mashayekhi, and J.A. Shields Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases Retina 32 7 2012 1363 1372
4. E. Kujala, T. Mäkitie, and T. Kivelä Very long-term prognosis of patients with malignant uveal melanoma Invest Ophthalmol Vis Sci 44 11 2003 4651 4659
5. P. Rietschel, K.S. Panageas, C. Hanlon, A. Patel, H.D. Abramson, and P.B. Chapman Variates of survival in metastatic uveal melanoma J Clin Oncol 23 31 2005 8076 8080
6. F. Pons, M. Plana, and J.M. Caminal Metastatic uveal melanoma: is there a role for conventional chemotherapy? A single center study based on 58 patients Melanoma Res 21 3 2011 217 222
7. S. Eskelin, S. Pyrhönen, M. Hahka-Kemppinen, S. Tuomaala, and T. Kivelä A prognostic model and staging for metastatic uveal melanoma Cancer 97 2 2003 465 475
8. J.J. Augsburger, Z.M. Corrěa, and N. Trichopoulos Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival Am J Ophthalmol 152 1 2011 5 9 e1
9. C.M. Mooy, and P.T. De Jong Prognostic parameters in uveal melanoma: a review Surv Ophthalmol 41 3 1996 215 228
10. C.L. Shields, S. Kaliki, M. Furuta, E. Fulco, C. Alarcan, and J.A. Shields American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients Ophthalmology 120 10 2013 2066 2071
11. E. Kujala, B. Damato, and S.E. Coupland Staging of ciliary body and choroidal melanomas based on anatomic extent J Clin Oncol 31 22 2013 2825 2831
12. A.D. Singh, and A. Topham Survival rates with uveal melanoma in the United States: 1973-1997 Ophthalmology 110 5 2003 962 965
13. L. Bergman, S. Seregard, B. Nilsson, G. Lundell, U. Ringborg, and B. Ragnarsson-Olding Uveal melanoma survival in Sweden from 1960 to 1998 Invest Ophthalmol Vis Sci 44 8 2003 3282 3327
14. P. Isager, N. Ehlers, and J. Overgaard Have choroidal and ciliary body melanomas changed during the period 1955-2000? Acta Ophthalmol Scand 82 5 2004 509 516
15. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11 Am J Ophthalmol 126 3 1998 362 372
16. Collaborative Ocular Melanoma Study Group Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15 Arch Ophthalmol 119 5 2001 670 676
17. J.J. Augsburger, Z.M. Corrěa, and A.H. Shaikh Quality of evidence about effectiveness of treatments for metastatic uveal melanoma Trans Am Ophthalmol Soc 106 2008 128 135 discussion 35-37
18. E.S. Gragoudas, K.M. Egan, and J.M. Seddon Survival of patients with metastases from uveal melanoma Ophthalmology 98 3 1991 383 389 discussion 90
19. M. Diener-West, S.M. Reynolds, and D.J. Agugliaro Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26 Arch Ophthalmol 123 12 2005 1639 1643
20. E.C. Hsueh, R. Essner, L.J. Foshag, X. Ye, H.J. Wang, and D.L. Morton Prolonged survival after complete resection of metastases from intraocular melanoma Cancer 100 1 2004 122 129
21. R. Kath, J. Hayungs, N. Bornfeld, W. Sauerwein, K. Höffken, and S. Seeber Prognosis and treatment of disseminated uveal melanoma Cancer 72 7 1993 2219 2223
22. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
23. M.A. Khattak, R. Fisher, P. Hughes, M. Gore, and J. Larkin Ipilimumab activity in advanced uveal melanoma Melanoma Res 23 1 2013 79 81
24. R. Danielli, R. Ridolfi, and V. Chiarion-Sileni Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy Cancer Immunol Immunother 61 1 2012 41 48
25. M.E. Polak, N.J. Borthwick, and P. Johnson Presence and phenotype of dendritic cells in uveal melanoma Br J Ophthalmol 91 7 2007 971 976
26. W.J. Meecham, D.H. Char, and S. Kaleta-Michaels Infiltrating lymphocytes and antigen expression in uveal melanoma Ophthalmic Res 24 1 1992 20 26
27. I. de Waard-Siebinga, C.G. Hilders, B.E. Hansen, J.L. van Delft, and M.J. Jager HLA expression and tumor-infiltrating immune cells in uveal melanoma Graefes Arch Clin Exp Ophthalmol 234 1 1996 34 42
28. E.H. Aarntzen, K. Bol, and G. Schreibelt Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma Cancer Res 72 23 2012 6102 6110
29. T.J. de Vries, D. Trancikova, D.J. Ruiter, and G.N. van Muijen High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma Br J Cancer 78 9 1998 1156 1161
30. K.P. Steuhl, J.M. Rohrbach, M. Knorr, and H.J. Thiel Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors Ophthalmology 100 2 1993 208 215
31. I.J. de Vries, G.J. Adema, C.J. Punt, and C.G. Figdor Phenotypical and functional characterization of clinical-grade dendritic cells Methods Mol Med 109 2005 113 126
32. C.G. Figdor, I.J. de Vries, W.J. Lesterhuis, and C.J. Melief Dendritic cell immunotherapy: mapping the way Nat Med 10 5 2004 475 480
33. I.J. de Vries, M.R. Bernsen, and W.J. Lesterhuis Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome J Clin Oncol 23 24 2005 5779 5787
34. N.C. Naus, A.C. Verhoeven, and E. van Drunen Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization Clin Cancer Res 8 2 2002 534 539
35. H. van Dekken, J.G. Pizzolo, V.E. Reuter, and M.R. Melamed Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes Cytogenet Cell Genet 54 3-4 1990 103 107
36. J.Y. Niederkorn Immune escape mechanisms of intraocular tumors Prog Retin Eye Res 28 5 2009 329 347
37. K.C. McKenna, and P.W. Chen Influence of immune privilege on ocular tumor development Ocul Immunol Inflamm 18 2 2010 80 90
38. K. Hallermalm, K. Seki, and A. De Geer Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes J Immunol 180 6 2008 3766 3774
39. J. Kan-Mitchell, P.E. Liggett, and W. Harel Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients Cancer Immunol Immunother 33 5 1991 333 340
40. R.P. Sutmuller, L.R. Schurmans, and L.M. van Duivenvoorde Adoptive T cell immunotherapy of human uveal melanoma targeting gp100 J Immunol 165 12 2000 7308 7715
41. F.F. Gonzalez-Galarza, S. Christmas, D. Middleton, and A.R. Jones Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations Nucleic Acids Res 39 database issue 2011 D913 D919
42. W. Maat, G.W. Haasnoot, F.H. Claas, N.E. Schalij-Delfos, G.M. Schreuder, and M.J. Jager HLA class I and II genotype in uveal melanoma: relation to occurrence and prognosis Invest Ophthalmol Vis Sci 47 1 2006 3 6
43. S. Edge, D.R. Compton, A.G. Fritz, F.L. Greene, and A. Trotti American Joint Committee on Cancer: Cancer Staging Manual Seventh Edition 2010 Springer New York
44. P. Terheyden, E.B. Bröcker, and J.C. Becker Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma J Cancer Res Clin Oncol 130 7 2004 395 399
45. T.F. Gajewski Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment Clin Cancer Res 13 18 Pt 1 2007 5256 5261
46. G. Prescher, N. Bornfeld, H. Hirche, B. Horsthemke, K.H. Jöckel, and R. Becher Prognostic implications of monosomy 3 in uveal melanoma Lancet 347 9010 1996 1222 1225
47. V.A. White, J.D. Chambers, P.D. Courtright, W.Y. Chang, and D.E. Horsman Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma Cancer 83 2 1998 354 359
48. V. Voelter, A. Schalenbourg, and S. Pampallona Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients Melanoma Res 18 3 2008 220 224
49. A.M. Lane, K.M. Egan, D. Harmon, A. Holbrook, J.E. Munzenrider, and E.S. Gragoudas Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis Ophthalmology 116 11 2009 2206 2212
50. I.J. de Vries, G.J. Adema, C.J. Punt, and C.G. Figdor Phenotypical and functional characterization of clinical-grade dendritic cells Methods Mol Med 109 2005 113 126
51. J. Tel, E.H. Aarntzen, and T. Baba Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients Cancer Res 73 3 2013 1063 1075
52. E.H. Aarntzen, I.J. De Vries, and W.J. Lesterhuis Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination Cancer Res 73 1 2013 19 29
53. D.H. Schuurhuis, P. Verdijk, and G. Schreibelt In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients Cancer Res 69 7 2009 2927 2934
54. C.G. Figdor, I.J. de Vries, W.J. Lesterhuis, and C.J. Melief Dendritic cell immunotherapy: mapping the way Nat Med 10 5 2004 475 480
55. E.H. Aarntzen, K. Bol, and G. Schreibelt Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma Cancer Res 72 23 2012 6102 6110
56. I.J. de Vries, M.R. Bernsen, and W.J. Lesterhuis Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome J Clin Oncol 23 24 2005 5779 5787
57. A.M. Van Nuffel, S. Tuyaerts, and D. Benteyn Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens J Immunol Methods 377 1-2 2012 23 36
58. V. Karanikas, C. Lurquin, and D. Colau Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus J Immunol 171 9 2003 4898 4904
59. W.J. Lesterhuis, G. Schreibelt, and N.M. Scharenborg Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used Cancer Immunol Immunother 60 2 2011 249 260
60. J.F. Jacobs, C.J. Punt, and W.J. Lesterhuis Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients Clin Cancer Res 16 20 2010 5067 5078
61. E.H. Aarntzen, I.J. De Vries, and W.J. Lesterhuis Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination Cancer Res 73 1 2013 19 29
62. E.H. Aarntzen, G. Schreibelt, and K. Bol Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients Clin Cancer Res 18 19 2012 5460 5470
63. J. Tel, E.H. Aarntzen, and T. Baba Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients Cancer Res 73 3 2013 1063 1075.